Table 3.

Significant Risk of Endpoints Associated With 103N and 181C Mutations Among Women With Prior Single-Dose Nevirapine (sdNVP) Exposure And Not In Women With No sdNVP Exposure

Prior sdNVP Exposure	Mutation	No. of Subjects	Primary Endpoint	P Valuea
No	No 103N	202	18%	1.00
	103N	17	18%
Yes	No 103N	69	17%	.009
	103N	45	40%
No	No 181C	203	18%	.72
	181C	14	21%
Yes	No 181C	96	19%	<.001
	181C	13	77%
No	No 190A	205	17%	.061
	190A	13	39%
Yes	No 190A	100	25%	.69
	190A	9	33%

Abbreviation: sdNVP, single-dose nevirapine.

^a Fisher exact test.